Natasja Brooijmans

This inventor holds 17 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Blueprint Medicines Corporation. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Natasja Brooijmans. Retrieved from https://idiyas.com/inventor/natasja-brooijmans

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 6.6

ph-index = 7

Forward Citations = 274(Granted Patents)

Location History:

Cambridge, MA (US) (2023)
Boston, MA (US) (2014 - 2024)

Company Filing History:

17 out of 71

Blueprint Medicines Corporation

patents

Years Active: 2014-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668585 - Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors (2026-06-30),

2. 12655129 - Heterocyclic EGFR inhibitors for use in the treatment of cancer (2026-06-16),

3. 12595265 - Inhibitors of activin receptor-like kinase (2026-04-07),

4. 12545684 - CDK2 inhibitors (2026-02-10),

5. 12172983 - EGFR inhibitors (2024-12-24),

6. 11970498 - CDK2 inhibitors (2024-04-30),

7. 11932648 - CDK2 inhibitors (2024-03-19),

8. 11718602 - EGFR inhibitors (2023-08-08),

9. 11634422 - Inhibitors of activin receptor-like kinase (2023-04-25),

10. 11046697 - Compounds and compositions useful for treating disorders related to NTRK (2021-06-29),

11. 10774070 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2020-09-15),

12. 10233186 - Inhibitors of activin receptor-like kinase (2019-03-19),

13. 10202365 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2019-02-12),

14. 10017512 - Compounds and compositions useful for treating disorders related to NTRK (2018-07-10),

15. 9340514 - Inhibitors of the fibroblast growth factor receptor (2016-05-17),

Title: Natasja Brooijmans: Pioneering Cancer Researcher and Inventor

Introduction: Natasja Brooijmans is a prominent inventor based in Boston, MA, who has made significant contributions to the field of cancer research. With a remarkable portfolio of 13 patents, she is dedicated to developing innovative therapeutic solutions to combat cancer through her work.

Latest Patents: Among her recent innovations, Natasja has developed EGFR inhibitors, which provide a compound useful for treating various cancers. This invention is represented by a specific structural formula or its pharmaceutically acceptable salts. Additionally, she has contributed to the development of CDK2 inhibitors, another vital therapeutic compound aimed at treating cancer.

Career Highlights: Natasja Brooijmans is currently affiliated with Blueprint Medicines Corporation, where she leverages her expertise in medicinal chemistry and cancer biology to advance groundbreaking cancer therapies. Throughout her career, she has focused on translating innovative ideas into actionable medical treatments.

Collaborations: Natasja has had the opportunity to collaborate with distinguished colleagues such as Joseph L. Kim and Neil Bifulco. These partnerships have enabled her to enhance her research and broaden the impact of their collective efforts in the fight against cancer.

Conclusion: As an accomplished inventor in the pharmaceutical sector, Natasja Brooijmans continues to make strides in cancer research. Her dedication to innovation and collaboration cements her legacy as a leading figure in the development of life-changing therapeutic solutions.

Profile summary based on public USPTO records.